Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113139 | 0.81 | ELANE (0.43) | ALDH1A1 | |
| SCHEMBL3680113 | 0.81 | POLB (0.41) | ALDH1A1POLBCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6379848 | 0.81 | ZAP70 (0.39) | ALDH1A1HRH4 | |
| SCHEMBL10899344 | 0.80 | ALDH1A1 (0.31) | ALDH1A1POLBHRH4 | |
| SCHEMBL29509040 | 0.79 | TLR8 (0.49) | ALDH1A1 | |
| SCHEMBL3407144 | 0.79 | HRH3 (0.50) | ALDH1A1HRH4 | |
| SCHEMBL29509020 | 0.77 | HCAR3 (0.43) | ALDH1A1POLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6268986 | 0.77 | HRH3 (0.31) | ALDH1A1POLB | |
| SCHEMBL8840758 | 0.77 | HRH3 (0.45) | ALDH1A1HRH4 | |
| SCHEMBL19692262 | 0.77 | ALDH1A1 (0.33) | ALDH1A1POLBADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010021897-A1 | NUCLEOSIDIC PHOSPHORAMIDITE CRYSTALLINE MATERIAL AND A PROCESS FOR PURIFYING THE SAME | MERCK SHARP & DOHME CORP. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-7057062-B2 | Process for manufacturing purified phosphorodiamidite | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| CN-1646544-A | Process for the preparation of purified diamidide phosphate | ISIS PHARMACEUTICALS INC (US) | 2005-07-27 | — | — | CN | disclosed |
| EP-1492800-A2 | PROCESS FOR MANUFACTURING PURIFIED PHOSPHORODIAMIDITE | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030225284-A1 | Process for manufacturing purified phosphorodiamidite | IONIS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087130-A2 | PROCESS FOR MANUFACTURING PURIFIED PHOSPHORODIAMIDITE | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225284-A1 | Process for manufacturing purified phosphorodiamidite | PHOSPHO1, PNP, OSGEP | ALDH1A1 4819/4885POLB 417/4885CYP1A2 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.